Involving members of the public in designing and running clinical trials is very important. Not only does it help us ensure the best interests of patients are always at the forefront of researchers’ minds, but it provides valuable insights into patients’ experiences that help to shape our research.
Our Trial Management Group benefits greatly from patient representation with the involvement of Sally Hayton. Similarly, Mat Baker brings the patient perspective to our Trial Steering Committee.
Tom Haswell was our PPI representative on the National Lung Matrix TMG from the outset until his death in November 2020. Tom made a lasting contribution to the trial and many other studies through national lung cancer research initiatives and Glasgow CTU.